Zevra Therapeutics, Inc.
ZVRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $23,612 | $27,461 | $10,161 | $28,650 |
| % Growth | -14% | 170.3% | -64.5% | – |
| Cost of Goods Sold | $7,417 | $2,945 | $222 | $2,059 |
| Gross Profit | $16,195 | $24,516 | $9,939 | $26,591 |
| % Margin | 68.6% | 89.3% | 97.8% | 92.8% |
| R&D Expenses | $42,095 | $39,806 | $19,803 | $10,161 |
| G&A Expenses | $0 | $0 | $15,343 | $8,701 |
| SG&A Expenses | $54,868 | $35,089 | $15,038 | $8,701 |
| Sales & Mktg Exp. | $0 | $0 | -$305 | $0 |
| Other Operating Expenses | $6,235 | -$775 | $17,663 | $0 |
| Operating Expenses | $103,198 | $74,120 | $52,504 | $18,862 |
| Operating Income | -$87,003 | -$49,604 | -$42,565 | $7,729 |
| % Margin | -368.5% | -180.6% | -418.9% | 27% |
| Other Income/Exp. Net | -$3,137 | $3,555 | $15,760 | -$16,250 |
| Pre-Tax Income | -$90,140 | -$46,049 | -$26,805 | -$8,521 |
| Tax Expense | $15,371 | $0 | -$33 | $34 |
| Net Income | -$105,511 | -$46,049 | -$26,772 | -$8,555 |
| % Margin | -446.9% | -167.7% | -263.5% | -29.9% |
| EPS | -2.28 | -1.3 | -0.78 | -2.11 |
| % Growth | -75.4% | -66.7% | 63% | – |
| EPS Diluted | -2.28 | -1.3 | -0.78 | -2.11 |
| Weighted Avg Shares Out | 46,251 | 35,452 | 34,489 | 29,766 |
| Weighted Avg Shares Out Dil | 46,251 | 35,452 | 34,489 | 29,766 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,175 | $4,541 | $1,513 | $261 |
| Interest Expense | $7,351 | $1,501 | $335 | $376 |
| Depreciation & Amortization | $6,389 | $1,006 | $944 | $257 |
| EBITDA | -$76,400 | -$43,542 | -$25,526 | -$7,888 |
| % Margin | -323.6% | -158.6% | -251.2% | -27.5% |